570 - Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)

Presenting Author(s)

• 

  Sujata M. Bhavnani, PharmD; MS; FIDSA

  Executive Vice President
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States

  Slides

Co-Author(s)

• JH

  Jeffrey P. Hammel, MS

  Director
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States
• CR

  Christopher M. Rubino, PharmD

  Executive Vice President
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States
• KL

  Karine Litherland, Ph.D.

  Basilea Pharmaceutica International Ltd
  Allschwil,, Basel-Landschaft, Switzerland
• KZ

  Kristie Zappas, PharmD

  Innoviva Specialty Therapeutics, Inc.
  Waltham, Massachusetts, United States
• MJ

  Mark E. Jones, PhD

  Basilea Pharmaceutica International Ltd., Allschwil, Switzerland
  Allschwil,, Basel-Landschaft, Switzerland
• TH

  Tony N. Hodges, M.D., FACP, FCCP

  Innoviva Specialty Therapeutics
  Waltham, Massachusetts, United States
• 

  Marc Engelhardt, MD (he/him/his)

  Dr.
  Basilea Pharmaceutica International Ltd., Allschwil, Switzerland
  Allschwil, Basel-Landschaft, Switzerland
• RW

  Rolf J. Wagenaar, MS

  Consultant
  Basilea Pharmaceutica International Ltd
  Somerville, New Jersey, United States